Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

NCT03015220 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03015220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03015220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
January 10, 2017
Completion date
July 12, 2018
Enrollment
458 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2